Most quit breakthrough weight-loss drug within a year Date: September 14, 2025 Source: European Association for the Study of Diabetes Summary: A massive Danish study reveals that despite the remarkable weight-loss benefits of semaglutide, more than half of adults without diabetes stop using it within a year
Tirzepatide is a newer medication that works slightly differently
GHK-Cu is a copper-binding tripeptide made of three amino acids (glycine, histidine, and lysine)
Dosing considerations for tirzepatide The tirzepatide dosing schedule typically starts at 2.5 mg weekly and can increase to 15 mg weekly
For optimal results and safety, semaglutide should be used under medical supervision, accompanied by lifestyle modifications like a balanced diet and regular exercise
Research on Sleep and Insomnia The original reason DSIP was studied was its effect on sleep